

Thyroid cancer Committee meeting 11

Date: 23/09/21 10:00-16:00

Location: Virtual meeting

Minutes: Confirmed

Committee members present:		
Richard Grünewald [RG] – Chair		(Present for notes 1 – 8)
Jeremy Davis [JD] – Topic advisor		(Present for notes 1 – 8)
John Buscombe [JB]		(Present for notes 1 – 8)
Preetha Chengot [PC]		(Present for notes 1 – 8)
Neil Cozens [NC]		(Present for notes 1 – 8)
Aimee Di Marco [ADM]		(Present for notes 6 – 8)
Fiona Eatock [FE]		(Present for notes 4 – 8)
Kate Farnell [KF]		(Present for notes 1 – 5)
Steve Hyer [SHY]		(Present for notes 1 – 8)
Jessica Lishak [JL]		(Present for notes 1 – 8)
Kate Newbold [KN]		(Present for notes 1 – 5)
Sonja Hoy [SH]		(Present for notes 1 – 8)
Iain Nixon [IN]		(Present for notes 1 – 8)
Anh Tran [AT]		(Present for notes 1 – 8)

In attendance:		
Carlos Sharpin [CS]	Guideline Lead	(Present for notes 1 – 8)
Catrina Charlton	NICE Guideline Commissioning Manager	(Present for notes 1 – 5)
Mark Perry [MP]	Senior Research Fellow	(Present for notes 1 – 8)
Alfredo Mariani [AM]	Health Economist	(Present for notes 1 – 8)
Vimal Bedia [VB]	Research Fellow	(Present for notes 1 – 4)
Angela Cooper [AC]	Senior Research Fellow	(Present for notes 1 – 8)
Sophie Carlisle [SC]	Research Fellow	(Present for note 6)
Yasmina Hedhli [YH]	Project Manager	(Present for notes 1 – 8)

Apologies:	
Jessica Lishak [JL]	GC member
Lina Gulhane [LG]	Head of Information Specialists

1. Welcome and objectives for the meeting
<p>The Chair welcomed the Committee members and attendees to the eleventh meeting on Thyroid cancer. The Committee members and attendees introduced themselves.</p> <p>The Chair outlined the objectives of the meeting, which included:</p> <ul style="list-style-type: none"> • TSH suppression vs no suppression • Duration of suppression • Information, education and support for patients, families and carers • Molecular testing
2. Confirmation of matter under discussion, and declarations of interest
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were TSH suppression vs no suppression, duration or suppression and molecular testing.</p> <p>The Chair and a senior member of the Developer's team noted that neither the interests previously declared did not prevent the attendees from fully participating in the meeting.</p>
3. Evidence review: TSH suppression vs no suppression
<p>VB presented the clinical evidence for TSH suppression vs no suppression. AM presented the health economic evidence. The GC drafted recommendations.</p>
4. Evidence review: Duration of suppression
<p>VB presented the clinical evidence for duration of suppression. AM presented the health economic evidence. The GC drafted recommendations.</p>
5. Evidence review: Information, education and support for patients, families and carers.
<p>AC presented the evidence for information, education and support for patients, families and carers. The GC drafted recommendations.</p>

6. Evidence review: Molecular testing
SC presented the clinical evidence for molecular testing. AM presented the health economic evidence. The GC drafted recommendations.
7. Health economic plan
AM provided an update on the health economic plan and asked for volunteers to join the health economics subgroup.
8. Any other business
There was no other business

Date of next meeting:

4 November 2021

Location of next meeting: Virtual meeting